June 19, 2019

CHAIN’s drug delivery platform and lead product, β-hydroxybutyrate, is highlighted in a new report ‘Catalysing Investment and Growth’, released by the BioIndustry Association this week. Our microbiome therapeutics are based on spores of Clostridium bacterial species. We have successfully demonstrated scale-up of bacterial spore production with our partners at Porton Biopharma Ltd as part of the Industrial Strategy […]

April 8, 2019

MARLOW & NOTTINGHAM, UK. — April 8, 2019 – UK microbiome therapeutics company CHAIN Biotechnology has appointed two new non-executive directors, Dr Nel Moore and Dr Robert Haigh to the Board. Dr Nel Moore has considerable experience in drug development with a track record taking therapeutics to market as former Global Product Vice President at […]

February 6, 2019

CHAIN has been awarded two grants to support its therapeutic delivery platform from Innovate UK (IUK), the UK’s innovation agency. The grant-funded projects will focus on the development and testing of two new biotherapeutics using CHAIN’s proprietary delivery platform CADDTM. The projects build on successful IUK funded projects that were used to develop and validate […]

January 9, 2019

NOTTINGHAM, UK. — January 9th, 2019 — CHAIN has joined EuropaBio as a full member after placing runner-up in the Biotech SME Awards announced in November. As part of this membership, CHAIN gains access to EuropaBio’s network and will receive updates from working groups operating in diverse areas such as IP, regulatory policy and personalised […]

December 19, 2018

In November, CHAIN moved research base from the University of Nottingham into independent lab and office space at the art deco MediCity building in Nottingham. The move coincides with the Company’s expansion, hiring Lab Manager Claire Evans earlier this year to oversee the move and Junior Scientist Matthew Allen more recently to begin work on […]

October 1, 2018

CHAIN features in a new explainer document on engineering biology from the UK Bioindustry Association (BIA) published today. Engineering Biology Explained discusses what these areas are all about, showcasing the important contributions made to these industries by UK bioscience companies and outlining the external environment required to ensure that these areas of innovation continue to benefit patients, […]

June 1, 2018

Ben Bradley, our Head of Partnerships and Licensing, is attending Gut-Brain Axis 2018, part of the Biotech Pharma Summit conference series in Paris September 6 & 7. This year’s event brings together leading scientists, physicians, and senior leaders to explore the brain and its engagement with the GI-nervous system axis in health and disease. Chief Executive Dr […]

March 26, 2018

UK biotech to manufacture novel medicines for Inflammatory Bowel Disease using spores of gut bacteria Three leading British biotechnology businesses have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines, targeting a range of clinical conditions through interaction with the human microbiome. The novel and highly innovative approach […]

February 28, 2018

CHAIN has been awarded £0.5M grant funding from Innovate UK, the UK’s Innovation agency, to expand its range of biotechnology products. Building on a successful synthetic biology program, the grants support further development of CHAIN’s proprietary Clostridium platform for therapeutic and specialty chemical applications. A two-year project will focus on the development of novel therapeutics […]

February 9, 2018

CHAIN plans to attend a record number of microbiome and biotech conferences over the next year to showcase our therapeutic platform and identify partners for the development of novel, targeted therapies. First up is the Spores Conference in April where our Technical Product Manager, Dr Daniela Heeg, will speak about CHAIN’s novel therapeutic delivery platform. […]